Skip to content

Model-informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment.

Aug 2026 · British Journal of Clinical Pharmacology · 0 citations · 38 references
Medicine

TL;DR

In Chinese populations, hepatic impairment and CYP2C9 polymorphisms increased etrasimod exposure, with the greatest increase observed in CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment (67% increase in AUCss).

Abstract

Aims

Etrasimod is an oral sphingosine-1-phosphate receptor modulator approved for moderate-to-severe ulcerative colitis. The impact of CYP2C9 polymorphisms and hepatic impairment on etrasimod exposure remains unclear. This study aimed to characterize their effects and identify clinically relevant dose adjustment strategies in Chinese patients.

Methods

A physiologically based pharmacokinetic model was developed and verified using in vitro metabolism and single-dose, multiple-dose and drug-drug interaction clinical pharmacokinetic data. The validated model was extrapolated to Chinese populations with different CYP2C9 genotypes and hepatic impairment severity to characterize exposure changes and optimize dosing.

Results

Most predicted pharmacokinetic parameters are within a twofold error range. At the approved dose of 2 mg once daily, the predicted median steady-state AUC0-24 and Cmax were 1976.95 ng·h/mL (95% prediction interval [PI]: 975.78-4144.29 ng·h/mL) and 98.40 ng/mL (95% PI: 52.9-190.51 ng/mL) in Caucasian subjects and 1988.82 ng·h/mL (95% PI: 814.91-4244.10 ng·h/mL) and 105.18 ng/mL (95% PI: 51.30-198.03 ng/mL) in Chinese subjects, respectively. In Chinese populations, hepatic impairment and CYP2C9 polymorphisms increased etrasimod exposure, with the greatest increase observed in CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment (67% increase in AUCss).

Conclusions

CYP2C9 polymorphisms and hepatic impairment increased etrasimod exposure, particularly when combined. Model-based exposure matching supported dose reduction to 1.5 mg once daily for most affected subgroups and to 1 mg once daily for CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment, providing quantitative support for individualized dosing.

View source

Similar papers

Open access Oct 2026

Dose Optimization of Cefazolin for Pediatric Patients with Renal Impairment Using Physiologically Based Pharmacokinetic Modeling (PBPK) in GastroPlus

Background/Objectives: Cefazolin is a first-generation cephalosporin antibiotic widely used for the treatment and prophylaxis of bacterial infections in both adult and pediatric populations. It is predominantly eliminated unchanged by the kidneys. Impaired renal function can reduce its clearance and increase systemic e...

A. Abdeen, Yousef A. Bin Jardan, Najia Rahim et al. · 0 citations
Open access Sep 2026

Pyridoxic Acid as a Novel Endogenous Biomarker for OAT-Mediated Clearance of Meropenem: A Population Pharmacokinetic Modeling and PK/PD-Response Analysis in Patients with Sepsis

PDA is a valuable translational biomarker for OAT-mediated clearance and is suggested to complement CLcr in characterizing meropenem clearance variability, establishing a key PD endpoint.

Zi-Han Lei, Hao Liang, Qin Cheng et al. · 0 citations
Open access Sep 2026

Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking.

BACKGROUND AND OBJECTIVE Understanding interindividual pharmacokinetic variability and potential for drug interactions is of clinical importance for pomalidomide given its long-term use in patients with relapsed and/or refractory multiple myeloma (RRMM). This study aimed to develop a physiologically based pharmacokinet...

Jeffry Adiwidjaja, A. Boddy, Andrew J. McLachlan · 0 citations
Open access Sep 2026

Pharmacokinetic and safety interactions between aildenafil and clarithromycin, cimetidine, or rifampin in healthy subjects.

AIMS Aildenafil citrate, an orally bioavailable phosphodiesterase type 5 (PDE5) inhibitor, is primarily metabolized by cytochrome P450 3A4 (CYP3A4). This study aimed to assess potential pharmacokinetic interactions between aildenafil citrate tablets and cytochrome P450 (CYP)3A modulators. METHODS This study involved...

Ran Xie, Nan Zhao, B. Jia et al. · 0 citations
Oct 2026

Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modeling.

The authors' model predicts that ceritinib co-administration substantially elevates rivaroxaban exposure and exploratory major bleeding risk, and predicts model-predicted dosing strategies comparable to standard monotherapy.

Jian-Wei Ren, Yi-Yao Li, Xin Zheng et al. · 0 citations
Open access Oct 2026

Impact of Body Weight and Combined UGT1A1 and NR1I2 Polymorphisms on Dolutegravir Pharmacokinetics Among Thai People Living with HIV: A Population Pharmacokinetic Analysis

Background/Objectives: Despite its role as a first-line therapy for Thai people living with HIV (PLWH), dolutegravir (DTG) exhibits significant pharmacokinetic (PK) variability influenced by both genetic and non-genetic factors. This variability may contribute to an increased incidence of neuropsychiatric adverse event...

A. Chanruang, Angela K. Birnbaum, S. Illamola et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.